Inventiva Showcases Breakthrough Phase 2 Trial Results
Inventiva, a clinical-stage biopharmaceutical company, is making headlines with its recent announcement regarding the Phase 2 LEGEND trial results of lanifibranor in combination with empagliflozin. These results are set to be presented at an upcoming prestigious liver health meeting. This exciting development underscores the company's commitment to finding effective treatments for metabolic dysfunction-associated steatohepatitis (MASH) and Type-2 Diabetes (T2D).
Details of the Upcoming Presentation
The celebration of scientific achievement will take place during the 75th Annual American Association for the Study of Liver Diseases (AASLD) meeting. This event is scheduled from November 15 to 19, providing a platform for medical professionals to engage with innovative research.
Abstract Title and Presentation Highlights
The abstract titled "Combination therapy of lanifibranor with empagliflozin: metabolic improvement in patients with Metabolic Dysfunction-Associated Steatohepatitis (MASH) and Type-2 Diabetes (T2D)" has been selected as a late breaker presentation. This recognition highlights the importance and timeliness of the findings, reflecting on significant advances in treating these challenging health conditions.
The Science Behind Lanifibranor
Lanifibranor, Inventiva's frontrunner product candidate, is an orally-administered small molecule that showcases remarkable potential in inducing antifibrotic and anti-inflammatory responses. By activating all three peroxisome proliferator-activated receptor (PPAR) isoforms, lanifibranor enhances beneficial metabolic changes in the body. Unlike its competitors that target fewer PPAR isoforms, lanifibranor is unique as it is the only pan-PPAR agonist in clinical trials for MASH/NASH.
Clinical Insights and Regulatory Milestones
Lanifibranor's well-balanced activation of PPAR?, PPAR?, and partial activation of PPAR? has resulted in a favorable tolerability profile noted in both clinical and preclinical studies. The FDA has granted it Fast Track and Breakthrough Therapy designations, further underscoring its potential significance in the treatment landscape for MASH/NASH.
About Inventiva's Strategic Focus
This French biopharmaceutical company is dedicated to developing innovative therapies that meet critical gaps in patient care, specifically targeting metabolic diseases. Currently, Inventiva is advancing lanifibranor through necessary phases while also maintaining a robust preclinical pipeline including drug candidates aimed at addressing a variety of medical needs.
Current and Future Clinical Trials
Inventiva's continued commitment to addressing metabolic diseases is exemplified by its pivotal Phase III clinical trial, NATiV3, which also focuses on adult patients suffering from MASH/NASH. With a well-rounded pipeline, including odiparcil for MPS VI treatment, Inventiva is strategically reviewing its clinical focuses to maximize development potential.
Contact Information for Inquiries
Inventiva is strong on communication, ensuring that stakeholders stay informed and engaged. Pascaline Clerc, PhD, the EVP of Strategy and Corporate Affairs, is reachable for press inquiries. Additional contact points are available for broader investor relations, ensuring transparency and accessibility for those interested in the company's future.
Frequently Asked Questions
What is the significance of the LEGEND trial results?
The LEGEND trial results signify a potential breakthrough in treating MASH and T2D, emphasizing the effectiveness of lanifibranor when combined with empagliflozin.
What are the key findings from the Phase 2 trial?
The key findings suggest that the combination therapy could lead to metabolic improvements for patients suffering from MASH and T2D.
Who are the authors presenting the study?
The study will be presented by a team of experts including Michelle Lai, Onno Holleboom, and others who contributed significantly to this clinical research.
What is the mechanism of action for lanifibranor?
Lanifibranor works by activating all three PPAR isoforms, helping to manage inflammation, fibrosis, and metabolic regulation in patients.
How can I get in touch with Inventiva for more information?
You can contact Pascaline Clerc at Inventiva via email for press inquiries or general questions about the ongoing trials and developments.
